BridgeMD
New treatment option for Alzheimer Disease, Early Onset
Official title MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
ClinicalTrials.gov ID: NCT06099587
What this study is testing
- What it's testing
- Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 80
You may be able to join if
- aged between 50 and 80
- native French speaking
- right-handed
- with a level of education equal to or higher than the Certificat d'Etudes Primaires (primary school leaving certificate)
- free of any medical or psychiatric condition likely to interfere with cognition, other than a diagnosis of SCD / MCI
You likely can't join if
- contraindications to MRI : Abdominal circumference + upper limbs stuck to the body \> 200 cm; Implantable pacemaker or defibrillator; Neurosurgical...
- sensory deficit interfering with experimental tests
- pregnant or breast-feeding women
- adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
- 7-items modified Hachinski ischemic score \>2 (Hachinski et al., 2012)
- Dementia (McKhann et al., 2011)
See the full eligibility criteria
- aged between 50 and 80
- native French speaking
- right-handed
- with a level of education equal to or higher than the Certificat d'Etudes Primaires (primary school leaving certificate)
- free of any medical or psychiatric condition likely to interfere with cognition, other than a diagnosis of SCD / MCI
- affiliated with a social security scheme
- having received oral and written information abou the protocol and having signed a consent form to participate in this research
- patients with 'subjective cognitive decline-plus' (hereafter 'SCD', criteria of Jessen et al., 2014) or patients with mild neurocognitive impairment due to Alzheimer's disease (hereafter 'MCI', criteria of Albert et...
- contraindications to MRI : Abdominal circumference + upper limbs stuck to the body \> 200 cm; Implantable pacemaker or defibrillator; Neurosurgical clips; Cochlear implants ; Neural or peripheral stimulator...
- sensory deficit interfering with experimental tests
- pregnant or breast-feeding women
- adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
- 7-items modified Hachinski ischemic score \>2 (Hachinski et al., 2012)
- Dementia (McKhann et al., 2011)
The study team makes the final eligibility decision.
Where it's taking place
- Rennes, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rennes, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.